Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
38 hedge funds and large institutions have $29.4M invested in Cellular Biomedicine Group, Inc. in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
12% more funds holding
Funds holding: 34 → 38 (+4)
6% more capital invested
Capital invested by funds: $27.6M → $29.4M (+$1.78M)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $312K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.69M |
| 2 |
BlackRock
New York
|
+$926K |
| 3 |
State Street
Boston,
Massachusetts
|
+$595K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$398K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$182K |
| 2 |
Morgan Stanley
New York
|
-$119K |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$73.1K |
| 4 |
Bank of New York Mellon
New York
|
-$41.6K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$7.12K |
CBMG Hedge Fund Activity: Q3 2018 in Review
38 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q3 2018, worth a combined $29.4M — up 6.5% from $27.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CBMG positions and 3 closed out — a net gain of 4 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Northern Trust, adding an estimated $1.69M. The largest seller was Manulife (Manufacturers Life Insurance), exiting entirely with an estimated $182K sold.
- 38 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q3 2018, up from 34 in Q2 2018.
- Funds reported $29.4M of Cellular Biomedicine Group, Inc. stock for Q3 2018, up 6.5% quarter-over-quarter.
- 7 funds opened new Cellular Biomedicine Group, Inc. positions in Q3 2018 and 3 closed out, a net change of +4 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q3 2018 was Northern Trust, an estimated $1.69M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q3 2018 was Manulife (Manufacturers Life Insurance), an estimated $182K sold.
Based on aggregated 13F filings for Q3 2018.